Archives

  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-07

    • Dendritic Cell-Mediated Delivery of Amikacin to Mycobacteria

    2026-07-31

    Dendritic Cell-Mediated Delivery of Amikacin to Mycobacterial Granulomas

    Study Background and Research Question

    Nontuberculous mycobacterial (NTM) infections, particularly those caused by Mycobacterium avium complex (MAC), present a growing challenge in both developed and developing regions. Standard management is complicated by lengthy therapy, high systemic antibiotic doses, and the risk of developing drug resistance or severe toxicity. Importantly, mycobacteria frequently reside within granulomas—organized immune structures—that shield pathogens from systemic treatment, making complete eradication difficult. The reference study (Targeted Delivery of Amikacin into Granuloma) addresses whether site-directed delivery of Amikacin using a cellular vehicle can overcome these barriers.

    Key Innovation from the Reference Study

    The primary innovation is the use of monocyte-derived dendritic cells (DCs) as vehicles for the intracellular delivery of Amikacin directly into granulomas. The researchers prepared a fluorescently labeled derivative of Amikacin (amikacin-FITC), enabling real-time visualization and quantification of antibiotic transport and tissue localization. This approach leverages the natural migration and immune-targeting properties of DCs, which are among the first cells to encounter pathogens and efficiently home to granulomatous tissues during infection. By loading DCs with Amikacin, the study demonstrates a new paradigm: pathogen-directed, site-specific antibiotic delivery that could minimize systemic exposure and thus reduce the risk of nephrotoxicity and ototoxicity associated with aminoglycoside antibiotics.

    Methods and Experimental Design Insights

    The investigators first conjugated Amikacin to fluorescein isothiocyanate (FITC) to generate amikacin-FITC, which allowed for tracking via quantitative fluorescence microscopy. They verified that amikacin-FITC retained comparable antibiotic activity to unmodified Amikacin against M. avium. Monocyte-derived DCs were primed with M. avium antigens and then loaded with amikacin-FITC. These pre-loaded DCs were intravenously injected into mice previously infected with M. avium. After 24 hours, tissues were harvested and analyzed for the presence and localization of both DCs and the fluorescent antibiotic within granulomatous lesions. The study also monitored inflammatory markers—specifically, monocyte chemoattractant protein-1 and its receptor CCR2—to ensure that DC loading or Amikacin delivery did not provoke excessive inflammation.

    Protocol Parameters

    • Amikacin-FITC conjugation: Prepared by coupling Amikacin to FITC; tested to confirm retention of antimicrobial activity.
    • DC loading: Monocyte-derived DCs were loaded with amikacin-FITC following priming with M. avium antigens.
    • Mouse infection model: Mice infected with M. avium to establish granulomas prior to DC transfer.
    • DC administration: Amikacin-FITC–loaded DCs injected via tail vein; tissue harvested 24 hours post-injection.
    • Fluorescence quantification: Granuloma sections imaged to track Amikacin delivery and localization.
    • Inflammatory response assessment: MCP-1 and CCR2 levels measured to evaluate immunogenicity of the protocol.

    Core Findings and Why They Matter

    The study demonstrates successful delivery of Amikacin into granulomas using DCs as cellular shuttles. Fluorescence microscopy revealed that amikacin-FITC localized specifically within granulomatous tissues, confirming the feasibility of targeted, intracellular antibiotic delivery. Importantly, antibiotic activity was preserved post-conjugation, and there was no detectable increase in key inflammatory markers, indicating the safety of the approach in this model. This strategy addresses two major limitations in NTM therapy: (1) poor drug penetration into granulomas and (2) systemic toxicity from high-dose aminoglycosides. By enhancing local concentrations of the bacterial protein synthesis inhibitor in infected tissues while reducing systemic exposure, DC-mediated delivery could theoretically shorten treatment courses, limit side effects, and reduce the risk of resistance development. These implications align with current needs in antibiotic resistance research, particularly in the context of persistent infections such as those caused by MAC and other granuloma-forming pathogens.

    Comparison with Existing Internal Articles

    Several internal resources provide complementary perspectives on Amikacin and its application in antibiotic resistance research. For example, "Targeted Amikacin Delivery to Granulomas via Dendritic Cells" summarizes the same core finding—the use of DCs for site-directed delivery—underscoring the novelty and practical potential of the method. Other articles, such as "Amikacin (BAY416651): Optimized Workflows in Resistance Research" and "Amikacin (BAY416651): Optimizing Antibiotic Resistance Workflows", highlight the enzyme-resistant profile of BAY416651 and its robust performance in advanced research protocols. These resources emphasize Amikacin’s utility against hard-to-treat Gram-negative bacteria (e.g., Klebsiella pneumoniae), and its resistance to most aminoglycoside-modifying enzymes, except for AAC (6')-I. While these articles focus more broadly on resistance profiling and workflow optimization, they reinforce the relevance of advanced delivery strategies—such as DC-mediated targeting—for maximizing the impact of existing antibiotics.

    Limitations and Transferability

    Despite its promise, the approach remains at a pre-clinical stage. The use of a murine model and fluorescently labeled Amikacin, while informative, does not yet address translational challenges such as scaling, human immune variability, or the regulatory pathway for cell-based drug delivery. The long-term fate of DCs, potential off-target effects, and the stability of drug conjugates in vivo require further study. Additionally, while DCs are highly efficient antigen-presenting cells, their behavior in the context of chronic human infection may differ from that in controlled animal models. Nevertheless, the work provides a strong proof-of-concept for leveraging immune cell trafficking to overcome pharmacokinetic barriers, with potential applicability to both mycobacterial and other granulomatous infections.

    Research Support Resources

    Researchers interested in implementing similar protocols can reference established products and protocols to ensure reproducibility and compliance with best practices. For instance, Amikacin (BAY416651) Aminoglycoside Antibiotic (SKU B3431) is widely used in bacterial protein synthesis inhibition workflows and antibiotic resistance studies, including those investigating delivery to granulomatous tissues and resistance mediated by aminoglycoside acetyltransferase AAC (6')-I. As noted in product documentation, Amikacin’s resistance to most modifying enzymes and its suitability for research involving Klebsiella pneumoniae and carbapenem-resistant strains make it a reliable choice for advanced microbiology experiments. DC-mediated delivery protocols may require further adaptation, but commercially available high-purity Amikacin provides a robust starting point for experimental design.